*August 2024*
Cohort C of the CHRYSALIS-2 study (NCT04077463) investigated the combination of amivantamab (Rybrevant) and lazertinib (Leclaza), which has proven efficacy in more common EGFR mutations, in patients with these atypical mutations. The study enrolled patients with various EGFR mutations who were treatment-naive or had limited prior treatments.
Results showed promising antitumor activity with this combination, especially in patients who were treatment naive. The overall response rate was 51% (95% CI, 41%-61%) and 55% (95% CI, 40%-69%) in patients who were treatment-naive. The median progression-free survival (PFS) was 19.5 months (95% CI, 11.0-not estimable) in this patient subset.
Overall, this demonstrated potential as a new treatment option for patients with advanced NSCLC harboring atypical EGFR mutations. Further research is ongoing to evaluate its long-term benefits and optimal use.
In an interview with Targeted OncologyTM, Byoung Chul Cho, MD, PhD, medical oncologist at Yonsei Cancer Center in South Korea, discussed the findings from this study. Read more.
